Cargando…
Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time?
BACKGROUND: Sargramostim [recombinant human granulocyte-macrophage colony-stimulating factor (rhu GM-CSF)] was approved by US FDA in 1991 to accelerate bone marrow recovery in diverse settings of bone marrow failure and is designated on the list of FDA Essential Medicines, Medical Countermeasures, a...
Autores principales: | Lazarus, Hillard M., Ragsdale, Carolyn E., Gale, Robert Peter, Lyman, Gary H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416151/ https://www.ncbi.nlm.nih.gov/pubmed/34484202 http://dx.doi.org/10.3389/fimmu.2021.706186 |
Ejemplares similares
-
Recombinant GM-CSF for diseases of GM-CSF insufficiency: Correcting dysfunctional mononuclear phagocyte disorders
por: Lazarus, Hillard M., et al.
Publicado: (2023) -
Safety and efficacy of sargramostim (GM‐CSF) in the treatment of Alzheimer's disease
por: Potter, Huntington, et al.
Publicado: (2021) -
Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (rhu GM-CSF) as Adjuvant Therapy for Invasive Fungal Diseases
por: Chen, Tempe K, et al.
Publicado: (2022) -
Immunomodulation of human intestinal T cells by the synthetic CD80 antagonist RhuDex®
por: Heninger, Anne-Kristin, et al.
Publicado: (2014) -
279. Inhaled Sargramostim (rhu GM-CSF) Leads to Enhanced SARS-CoV-2 Virus-Specific Immune Response and Viral Clearance: Results of the Biomarker Cohort of a Randomized, Double-Blind, Placebo-Controlled Phase 2b Trial in Non-Hospitalized Patients with COVID-19
por: Joshi, Ila, et al.
Publicado: (2023)